Histologically confirmed intracranial germ cell tumors; an analysis of 62 patients in a single institute.
This study was undertaken to document the clinicopathologic characteristics of histologically verified, primary intracranial germ cell tumors (GCTs), determine treatment outcomes, and to identify prognostic factors. The records of 62 patients (45 males and 17 females) with a primary intracranial GCT were retrospectively analyzed. Mean patient age was 18 years, and median follow-up was 41 months. The most common histological subtypes were germinoma (48.4%), followed by mixed GCT (27.4%), and teratoma (19.4%). In 23 patients (37.1%), disease onset occurred between 16 and 20 years. Germinomas and malignant non-germinomatous germ cell tumors were most prevalent in the pineal gland, suprasellar region, and basal ganglia, whereas teratomas dominated at other sites. Synchronous bifocal GCTs were found in six patients. Five-year overall survival (OS) rates according to a therapeutic classification proposed by Sawamura were 82.93%, 83.08%, and 64.71% in the good, intermediate, and poor prognosis groups, respectively (P = 0.2839). Five-year OSs in patients with normal tumor marker (alphaFP or betaHCG) and patients with elevated marker were 85.26% and 66.96%, respectively (P = 0.0568). Five of six patients with alpha-fetoprotein (alpha-FP) of >1,000 ng/ml succumbed to disease, whereas all five patients with a beta-human chorionic gonadotropin of >1,000 mIU/ml survived. Mixed GCTs are more common in Korea than in the West. Sawamura's classification of intracranial GCT may be a fine tool for stratifying patients' survival. Patients with elevated tumor marker levels may appear to have poorer OS independent of histology. In particular, high titers of alpha-FP seem to impact prognosis.
Lee
Dakeun
D
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul 135-710, Republic of Korea.
Suh
Yeon-Lim
YL
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007231:Infant, Newborn; D053208:Kaplan-Meier Estimate; D007723:Korea; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult
D014408:Biomarkers, Tumor